Saturday, October 20, 2012

Mobile revolution, economy trip up tech giants

SAN FRANCISCO (Reuters) - Mobile may be the future for technology, but even with the worldwide proliferation of high-powered devices like smartphones and tablets, some companies are struggling to maintain consistent revenue streams.

Earnings disappointments this week from Intel Corp, Microsoft Corp, Google Inc and AMD underscore how Silicon Valley, both the old guard and new, is struggling to profit from consumers' waning love affair with the stalwart PC and infatuation with mobile -- the most significant tectonic shift in the industry since the advent of the Internet.

That bodes ill for companies reporting next week that are highly leveraged to mobile advertising and services -- most famously Facebook Inc, which raised a tumult by warning about over-inflated expectations of its mobile business just before its seminal IPO.

Amazon and Apple Inc are expected to fare better, analysts say. Apple, which reports Thursday, is struggling with capacity constraints and supply hiccups -- but analysts contend that's a good problem to have because it's spurred by raging mobile hardware demand.

Amazon and eBay Inc, meanwhile, are succeeding in reaching consumers through mobile devices, particularly Amazon with its cut-rate Kindle Fire tablets. About 800,000 shoppers made their first-ever eBay purchase through a mobile device.

But others are struggling.

"Companies are realizing that it is not easy to find a formula that works with mobile," Gartner analyst Carolina Milanesi said. "Mobile is not proving to be as straightforward as people thought."

Signs that some of the most innovative of today's Silicon Valley titans are struggling with how to make money off mobile users come at a bad time for an industry already struggling with a worsening macroeconomic environment.

The biggest stunner was perhaps Google, which shed more than $20 billion of market value after it reported that its core advertising business had slowed. Critics said it was no anomaly.

"Click prices declined for the fourth consecutive quarter after rising for eight consecutive quarters before then. That's a negative. This is the mobile problem," said BGC analyst Colin Gillis.

Then there is Zynga, the poster child for mobile transition woes. In 2011 the casual games maker was a consumer Internet darling. In 2012, it has cut its outlook twice and lost three-quarters of its market value amid a lack of mobile hits, leading analysts to warn of massive layoffs.

Google CEO Larry Page, however, argued the shift represented a long-term opportunity.

"We're really starting to live in a new reality," he told analysts on a conference call. "It will create a huge new universe of opportunities for advertisers, where they ... will be dynamically adapting across a whole bunch of different devices, to reach the right audiences at the right time."

Internet companies in China, the world's largest Internet market by number of users, are also struggling to make money from those who access the Internet from mobile devices. Top China search engine Baidu Inc saw its shares tumble last week after Credit Suisse downgraded it to "underperform" on concerns about its money-making plans.

At the end of June, the number of Chinese users accessing the Internet from mobile phones surpassed those accessing the Internet via personal computer. Because of this trend, many Chinese Internet companies such as social-networking and online games firm Tencent Holdings have upped their mobile Internet offerings in order to capture growth.

"If you look at the evolution of mobile Internet, social networking is usually the first to spread around the world, followed by games and then advertising," said Elinor Leung of CLSA. "You have stages to mobile Internet development, but eventually everyone will be there".

FROM BAD TO WORSE

Perhaps hardest-hit are Intel and others closely tied to the PC chain. Intel's weak outlook for the fourth quarter ended any hopes the PC market would pick up at year's end. While Intel dominated that space in its prime, in smartphones its market share is less than 1 percent.

Intel's one-time rival AMD is in even worse shape, saying this week it will cut 15 percent of its staff -- more than 1,600 people -- as part of yet another restructuring to cut costs while it tries to figure out its future.

On Thursday, Microsoft revealed a 22 percent dive in quarterly profit as sales of computers running its Windows operating system dipped.

Marvell, yet another chipmaker being battered by the lagging PC market, on Thursday cut its revenue outlook by as much as 10 percent as its customers in the storage business suffered.

WINNERS WIN

Those doing best are the one with an established foothold in mobile, having figured it out years earlier.

Verizon Communications posted a record quarterly profit on the strength of the wireless business it co-owns, which came largely from demand for the iPhone.

Apple's ubiquitous handset even figured in the blockbuster $20 billion purchase of a majority in Sprint Nextel Corp by Softbank Corp. Softbank, the first to offer the phone in Japan, was said to admire Sprint's efforts to bring the device to its own network.

The memory maker SanDisk also easily beat expectations for the third quarter, as demand for chips to be used in smartphones and tablets drove up pricing.

If technology companies only had to deal with a platform transition, that would be one thing. The problem is they are struggling with that transition in the face of a weak economy, when technology upgrades are often the first budget line item to be cut and consumer spending crumbles.

"It seems like the macro conditions certainly deteriorated in the third month, and no tech company will be immune to it," said Trip Chowdhry, analyst at Global Equities Research.

(Reporting By Noel Randewich, Gerry Shih and Alexei Oreskovic in San Francisco, Bill Rigby in Seattle, Nicola Leske in New York and Melanie Lee in Shanghai; Writing by Ben Berkowitz; Editing by Edwin Chan and Ken Wills)

Source: http://news.yahoo.com/mobile-revolution-economy-trip-tech-giants-004639103--sector.html

v tech top model all stars americas next top model mark buehrle mark buehrle rick perry ad rick perry ad

Video: Gregory: Candidates in ?dead heat?

Sorry, Readability was unable to parse this page for content.

Source: http://video.today.msnbc.msn.com/today/49474900/

uk vs louisville university of kansas buckeye west side story final four 2012 bridesmaids winning lottery numbers

Monday, October 8, 2012

Battling harmful water toxins

ScienceDaily (Oct. 8, 2012) ? University of Ulster scientists are collaborating with international research partners to develop a new 'clean' technology to destroy water toxins caused by harmful algal blooms.

The research team, which is led by Dr Tony Byrne and includes Dr Patrick Dunlop and Dr Jeremy Hamilton, is based at NIBEC, Ulster's Nanotechnology and Integrated Bioengineering Centre at the Jordanstown campus where clean technology is a key research theme.

Dr Byrne explains: "Clean Technology is a term used to describe knowledge-based products or services that improve operational performance, productivity or efficiency, while reducing costs, inputs, energy consumption, waste or pollution.

"The increase of harmful algal blooms in estuaries and freshwater aquatic systems around the world is a major global problem because of the serious threat they pose to wildlife, livestock and humans," he said.

The seriousness of the problem on a local scale was highlighted this summer when harmful algal blooms were spotted on Loughbrickland Lake close to Banbridge in Co Down, and Moor Lough near Strabane, Co Tyrone. Both lakes, which are popular with anglers and used for water based recreation activities, were closed to members of the public for several weeks.

Algal blooms occur naturally but not all pose a risk to humans or animals. However, an increased supply of limiting nutrients in water due to pollution will increase the likelihood of harmful algal blooms.

Dr Tony Byrne continues: "Blooms containing cyanobacteria, sometimes called blue-green algae, can pose a serious threat, as these micro-organisms can produce and release a variety of cyanotoxins. These toxins include hepatotoxins, dermatotoxins, and neurotoxins with extremely high toxicity.

"Titanium dioxide is a white powder which is used in sunblock, paint, cosmetics and even some food products (E171). It is a non-toxic pigment but when excited by ultra violet light (UV), it becomes a powerful catalyst capable of destroying pollutants in water.

"This process is called photocatalysis and our challenge is to increase the solar efficiency because sunlight contains only a small proportion of UV. We have already demonstrated the destruction of the cyanotoxins under laboratory conditions using new catalysts under solar light but we need to fully understand the mechanism."

The Ulster researchers are funded by the Department for Employment and Learning under the US-Ireland R&D Partnership initiative involving Northern Ireland, Republic of Ireland, and the USA. They are collaborating with experts in the USA: Professor Dion Dionysiou from the University of Cincinnati and Professor Kevin O'Shea from Florida International University, funded by the National Science Foundation (USA). Dr Suresh Pillai is the main collaborator from the CREST Centre, Dublin Institute of Technology. He is funded by Science Foundation Ireland. This research project also delivers the objectives of the cross boarder collaboration initiative, EHSI (Environmental Health Sciences Institute) involving strategic partnerships with the University of Ulster and Dublin Institute of Technology.

The collaborators are involved in a number of other research projects exploring the use of other advanced oxidation processes for the removal of cyanotoxins from water sources.

Dr Byrne is course director for the BEng (Hons) degree in Clean Technology. When the course was introduced by the School of Engineering at the Jordanstown campus in 2009 Ulster became the only university in the UK or Ireland to offer an engineering course dedicated to Clean Technology.

The first intake of students will graduate next summer and Dr Byrne said he is optimistic about the growing employment opportunities in the Clean Technology sector.

"Clean Technology or 'Cleantech' is attracting billions of dollars of investment and carries the hopes of a low-polluting and sustainable future. There are excellent job prospects opening up for graduates who can contribute to this growing multi-billion dollar industry sector.

"Global issues such as energy supply, environmental pollution and access to clean water demand innovative solutions and our research is contributing to these technological advances which create opportunities for increased economic growth," said Dr Byrne.

Background information

Harmful algal blooms

Harmful algal blooms have threatened beaches, drinking water sources, and even water based activities around the boating venue for the 2008 Olympic Games in Beijing, China. They appear to be increasing along the coastlines and in the surface waters of the United States, according to the National Oceanic and Atmospheric Administration (NOAA). HSB epidemiologists have led a number of studies to investigate the public health impacts of blue-green algae blooms and Florida red tide. The studies have demonstrated that there is the potential for exposure to potent HAB-related toxins during recreational and occupational activities on water bodies with ongoing blooms.

Titanium Dioxide

Titanium dioxide is a naturally occurring oxide of the element titanium. It has a number of industrial applications. Because of its high refraction properties, titanium dioxide has earned it the nickname 'titanium white'. For this reason, it is often included in many cosmetic preparations to reflect light away from the skin. It is also a major component of sun block to deter the absorption of ultraviolet (UV) rays from the sun, the concentration of which determines the product's Sun Protection Factor, or SPF. Titanium dioxide is used to enhance the white colour of certain foods and is also used to brighten toothpaste and some medications.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by University of Ulster.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Note: If no author is given, the source is cited instead.

Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/top_environment/~3/lbToRZT2_-I/121008082957.htm

the village dallas fort worth tornado dallas tornadoes dallas weather nike nfl uniforms ben and jerrys free cone day tornado in dallas texas

Lilly drug may slow memory loss in mild Alzheimer's

(Reuters) - Eli Lilly and Co said its experimental Alzheimer's drug led to a 34 percent reduction in memory decline for patients with mild symptoms over a period of 18 months, giving it potential ammunition to seek approval for the medicine that showed no benefit in more advanced stages of the disease.

Shares of Eli Lilly rose as much as 5.6 percent on Monday, to levels not seen since April of 2008, as some investors were encouraged that the improvement could warrant consideration from the U.S. Food and Drug Administration.

Lilly in August said the drug, solanezumab, did not meet the primary goal of halting progression of the memory-robbing disease in patients with mild-to-moderate symptoms in two late-stage trials.

But while many rival compounds have been relegated to the scrap heap after similar failures, Lilly indicated at the time that there were signs that solanezumab prevented cognitive decline for people at an earlier stage of the disease.

On Monday, the company presented results on the drug pooled from the two large studies that focused only on those with mild Alzheimer's.

"Today's data supports the view that solanezumab may be active in early Alzheimer's patients but that further clinical work will likely be needed prior to FDA approval of the product," said J.P. Morgan analyst Chris Schott, adding that any drug that slows Alzheimer's would have "multibillion-dollar annual sales potential."

Some 5 million Americans and nearly 36 million people worldwide are believed to have the disease and its prevalence is expected to grow as the world's population lives longer. By 2050, the number of Americans aged 65 and older with Alzheimer's may triple, according to the Alzheimer's Association.

Lilly badly needs new drugs to offset sales declines of its treatments facing generic competition. Company executives said the new data could give solanezumab a fighting chance.

"Today there are no medicines that slow progression of Alzheimer's and we think that ought to be considered as we go talk to regulators," David Ricks, head of biomedicines for Lilly, said in a telephone interview.

"We'll make the argument this data is important in view of the high unmet need. But ultimately it's the FDA's judgment to make in terms of whether to let the drug on (the market) with these data," Ricks said.

THEORY ON TREATMENT

The newly released data did not show that solanezumab offered protection against the loss of physical function.

But it will likely lend further credence to the theory that Alzheimer's must be attacked early in the progression of the disease for drugs to have an impact.

Dr. Ronald Petersen, director of the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minnesota, threw out a note of caution about the drug's prospects.

"What you are seeing in the data is statistically significant," he said. "But it's hard to say that this is going to be meaningful clinically."

Dr. David Drachman, professor of neurology at the University of Massachusetts Medical School, questioned the significance of pooled memory findings culled from failed studies.

"The data cannot be regarded as significant," he said. "They did not prove it works."

Initial data unveiled in August created doubts about whether the Lilly drug could be approved by the FDA without large new studies. It followed disappointing results for Pfizer Inc's and Johnson & Johnson's bapineuzumab, which also failed in pivotal studies. Both treatments block a protein called beta amyloid that forms plaque deposits on the brain.

"Our committee is encouraged by the results of the solanezumab studies," Dr. Rachelle Doody, who presented the data at the American Neurological Association meeting, said in a statement. "They support amyloid as a target for future Alzheimer's research."

Doody, an Alzheimer's specialist from Baylor College of Medicine in Houston, was a member of the steering committee for the Alzheimer's Disease Cooperative Study that conducted an independent analysis of the solanezumab data.

In one of the two Lilly studies called Expedition1, mild Alzheimer's patients experienced a 42 percent reduction in decline in cognitive function after 18 months of treatment, which was deemed to be highly statistically significant.

In the Expedition2 study, a 20 percent reduction seen in cognitive, or memory, decline among mild Alzheimer's patients was not statistically significant.

Lilly reached the 34 percent reduction by combining data from the two studies, which it said had been pre-planned and was legitimate because the design of the two studies was nearly identical. By combining the studies, Lilly said, it had a greater number of mild Alzheimer's patients for purposes of data analysis.

Eli Lilly shares ended up $2.55, or 5.3 percent, at $50.78 on the New York Stock Exchange.

(Reporting By Ransdell Pierson and Bill Berkrot; Additional reporting by Toni Clarke in Boston; Editing by Michele Gershberg, Richard Chang, Maureen Bavdek and Tim Dobbyn)

Source: http://news.yahoo.com/lilly-drug-may-help-mild-alzheimers-studies-172228743--finance.html

Ryan Lochte Montenegro Olympic Games Dana Vollmer phillies phillies Ryan Dempster

Apple begins shipping its Lightning to 30-pin adapter at the speed of... freight

Apple begins shipping its Lightning to 30pin adapter at the speed of freight

iPhone users with a flotilla of 30-pin devices, desperate to restore connectivity with their newest handset's natty connector, can rest easy. Cupertino has contacted several Australians who pre-ordered the 30-pin to Lightning adapter to tell them they can expect the first units to arrive tomorrow. The Stateside store is still promising a generic "October" launch, but it can't be too far away if the Antipodeans are getting theirs.

Filed under: , ,

Apple begins shipping its Lightning to 30-pin adapter at the speed of... freight originally appeared on Engadget on Mon, 08 Oct 2012 08:22:00 EDT. Please see our terms for use of feeds.

Permalink   |  sourceMacRumors  | Email this | Comments


Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/pJpwb2nmnHg/

vanessa minnillo super tuesday epidemiology total eclipse of the heart jionni lavalle earthquake san francisco donald payne